In Vitro Diagnostics (IVD) Market - Forecast, 2012 - 2020 by True Market Research
In Vitro Diagnostics (IVD) Market - Forecast, 2012 - 2020 by True Market Research.com
In Vitro Diagnostics (IVD) provide critical information about the physiological and pathological state of body for effective health and drug/therapy monitoring. In 2011, North America and Europe occupied majority share of the in vitro diagnostics market due to the high healthcare expenditure and structured association of clinical laboratories. On the other hand, market players in the in vitro diagnostics market are keen to accelerate their growth by capitalizing on unmet opportunities present in the emerging economies. Although clinical chemistry IVDs led the market in 2011 across the US, India, and China market, the growth in the molecular diagnostics segment is forecasted owing to their efficacy in the early detection of the disease.
Increasing ageing population and rising cases of infectious diseases and chronic diseases – such as cardiovascular diseases, diabetes, cancer, and sexually transmitted diseases – are significant growth drivers of this market. Besides this, escalating health expenditure and increasing demand for advanced and automated diagnostics technologies are likely to drive the in vitro diagnostics market. However, on the other hand, reimbursement issues and the existence of ambiguity in the regulatory environment are restraints for this market. Despite this, the emerging molecular diagnostics and epigenomics-based diagnostics segments are expected to provide considerable growth opportunities in this market. Even, collaborations among diagnostic and pharmaceutical companies for research and development will help this market grow in the near future.
The global in vitro diagnostics market is segmented into markets by technique, product type, application, end users, and geography. The global in vitro diagnostics market by technique is segmented as immunoassay/immunochemistry, clinical chemistry, hematology, coagulation, microbiology, molecular diagnostics
In Vitro Diagnostics (IVD) provide critical information about the physiological and pathological state of body for effective health and drug/therapy monitoring. In 2011, North America and Europe occupied majority share of the in vitro diagnostics market due to the high healthcare expenditure and structured association of clinical laboratories. On the other hand, market players in the in vitro diagnostics market are keen to accelerate their growth by capitalizing on unmet opportunities present in the emerging economies. Although clinical chemistry IVDs led the market in 2011 across the US, India, and China market, the growth in the molecular diagnostics segment is forecasted owing to their efficacy in the early detection of the disease.
Increasing ageing population and rising cases of infectious diseases and chronic diseases – such as cardiovascular diseases, diabetes, cancer, and sexually transmitted diseases – are significant growth drivers of this market. Besides this, escalating health expenditure and increasing demand for advanced and automated diagnostics technologies are likely to drive the in vitro diagnostics market. However, on the other hand, reimbursement issues and the existence of ambiguity in the regulatory environment are restraints for this market. Despite this, the emerging molecular diagnostics and epigenomics-based diagnostics segments are expected to provide considerable growth opportunities in this market. Even, collaborations among diagnostic and pharmaceutical companies for research and development will help this market grow in the near future.
The global in vitro diagnostics market is segmented into markets by technique, product type, application, end users, and geography. The global in vitro diagnostics market by technique is segmented as immunoassay/immunochemistry, clinical chemistry, hematology, coagulation, microbiology, molecular diagnostics